Odyssey Health, Inc. Makes Statement Regarding its

0
105


Las Vegas Nevada, Sept. 30, 2022 (GLOBE NEWSWIRE) — Odyssey Health, Inc. (OTC: ODYY), f/okay/a Odyssey Group International, Inc., (the “Company” “Odyssey”) an organization targeted on growing a singular drug to deal with concussion has determined to dissolve its sports activities advisory board.

The sports activities advisory members have been outspoken advocates for concussion prevention and for the significance of discovering accountable remedies. We created the advisory board to extend consciousness of our mission to deliver a much-needed pharmaceutical for a situation that at present has no FDA authorised remedy. We have lately accomplished a Phase I human trial the place our drug was confirmed to be secure and nicely tolerated. We are excited in regards to the potential of initiating a Phase II trial to find out the efficacy and security of the drug in concussed sufferers.

The press has misrepresented Odyssey Health, Inc.  Odyssey has by no means instantly or not directly obtained cash from state or federal authorities sources to fund the drug growth. Odyssey shouldn’t be concerned in any litigation. Odyssey Health, Inc. bought the mental property and rights to the drug on March 1, 2021.  The cash to fund the drug growth has come from accredited traders. The Company contacted the press to advise of the information and misstatements.

In order to maintain our focus, the Company has determined to dissolve the sports activities advisory board, because it has prompted distraction to our essential work being carried out. Odyssey needs to proceed its give attention to this vital drug candidate in hopes of offering a much-needed remedy.  The Company will stay dedicated to bringing merchandise to market that present an answer to unmet medical wants.

See also  Katherine Taylor of Pleasant Plains, AR Celebrates 100th Birthday

About Odyssey Health Inc. (previously Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical firm with a spotlight within the space of life-saving medical options. Odyssey’s company mission is to create, purchase and develop distinct belongings, mental property, and distinctive applied sciences that present significant medical options. The firm is concentrated on areas which have an recognized technological benefit, present superior medical utility, and have a considerable market alternative. For extra data, go to the corporate’s web site at www.odysseyhealthinc.com.

About PRV-002
PRV-002 is a totally artificial, non-naturally occurring neurosteroid being developed for the remedy of mTBI (concussion). In preclinical research, PRV-002 has demonstrated equal, if not superior, neuroprotective results in comparison with associated neurosteroids. Animal fashions of concussion demonstrated that PRV-002 reduces the behavioral pathology related to mind harm signs similar to reminiscence impairment, anxiousness and motor/sensory efficiency. Additionally, PRV-002 is lipophilic and may simply cross the blood-brain barrier to quickly get rid of swelling, oxidative stress and irritation within the mind whereas restoring correct blood move. 

Forward-Looking Statements
This information launch could include forward-looking statements throughout the that means of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are primarily based upon our present expectations and communicate solely as of the date hereof.

Inquiries:
Odyssey Health
data@odysseyhealthinc.com



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here